In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

The European Randomized study of screening for prostate cancer (ERSPC) demonstrated a reduction in prostate cancer (PC) mortality via PSA-based screening. We evaluated whether treatments for ...

When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru ...

Post-Treatment SPECT Imaging for Personalized Radiopharmaceutical Therapy "Presentation" - Carlos Uribe ...

Postoperative bladder spasm is a prevalent complication during the indwelling catheter period after radical prostatectomy (RP), affecting patient recovery and quality of life. This study aimed to ...

Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber ...

Despite this favorable survival estimate for localized diseases, prostate cancer is still predicted to contribute to 35,250 new cancer deaths in 2024. 1 This accounts for 5.8% of all cancer-driven ...

The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified ...

Muscle-invasive bladder cancer (MIBC) represents a genetically heterogeneous disease with limited prognostic markers. This study aimed to validate the prognostic relevance of combined alterations in ...